Altnia is a privately-held technology incubator and R&D company based in Melbourne Australia.

Our aim is to accelerate the solutions to problems impacting people around the world.

Altnia Innovation Pty Ltd, formed in 1992, is the main entity, based in Melbourne Australia. AI has acted as a private venture capital fund and management company for more than 30 years.

The Altnia group has spawned 4 publicly listed companies that have raised in excess of A$150m to date.

Products harnessing artificial intelligence and machine learning is part of our recent focus.

Drug development, stem cell therapies, regenerative medicine and additive gene therapies are also in our scope.

Our team has expertise in AI, machine learning, regenerative medicine, drug discovery, diagnostics, medical devices, exosome manufacture, cellular therapy and acellular (cell-free) therapies.

How We Work

It usually starts with identifying a problem or large unmet need, and then inventing the technology to make it possible – what Peter Thiel describes as zero-to-one.

Altnia typically instigates projects itself and invests in early-stage projects until the IP is ready to be supported by external investors.

Some technologies become the basis for a public company, as with Rectifier Technologies, Cynata, Nyrada and Exopharm. Others build towards exits and trade-sale.

Altnia often uses its R&D resources to generate valuable new IP and patents, and sometimes in licenses IP from other sources if needed.

Altnia has established collaborations around Melbourne and Parkville and leverages access to core-facilities and innovative researchers at leading institutions anywhere in the world.

We have extensive experience in in-licensing technologies, and commercialisation of technology.

ALTNIA GROUP Portfolio of COMPANIES

Public companies

Rectifier Technologies Ltd (ASX:RFT) co-founded by Ian Dixon as CEO in 1992. Rectifier Technologies is an Australian company with a global presence, specialising in developing and manufacturing high reliability and high efficiency power conversion products. Present market cap is around $68m. RFT is active in the Electric Vehicle charger industry.

Cynata Therapeutics Ltd (ASX:CYP) formed from Cynata Inc. co-founded by Ian Dixon in 2011. Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company developing disruptive regenerative medicine products using adult stem cells.

Exopharm (ASX:EX1) founded by Ian Dixon in 2013 and listed on the ASX in 2018 with Ian Dixon as Managing Director and main shareholder. Exopharm (ASX:EX1) is a leader in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes for use as a drug-delivery chassis. Exopharm has 3 granted US patents on the LEAP technology co-invented by Ian Dixon.

Nyrada Inc. (ASX:NYR) co-founded by Ian Dixon in 2017 through the acquisition of Altnia Group company Cardio Therapeutics Pty Ltd by Noxopharm Ltd (ASX:NOX). Nyrada is a drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. Nyrada has a granted US patent on a cardiovascular PCSK9 inhibitor co-invented by Ian Dixon.

Private Companies

Sense Systems Pty Ltd – neuromorphic AI

Regerna Pty Ltd – regenerative medicine

Suono Music Systems Pty Ltd – AI music system

Contact

Management

Dr Ian Dixon

Director and Founder

p: +61 3 9894 4555

m: 0418 561 907

e: ian.dixon@altnia.com